AU2016350939B9 - Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases - Google Patents

Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases Download PDF

Info

Publication number
AU2016350939B9
AU2016350939B9 AU2016350939A AU2016350939A AU2016350939B9 AU 2016350939 B9 AU2016350939 B9 AU 2016350939B9 AU 2016350939 A AU2016350939 A AU 2016350939A AU 2016350939 A AU2016350939 A AU 2016350939A AU 2016350939 B9 AU2016350939 B9 AU 2016350939B9
Authority
AU
Australia
Prior art keywords
virus
influenza
protein
sequence
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016350939A
Other languages
English (en)
Other versions
AU2016350939B2 (en
AU2016350939A1 (en
AU2016350939A2 (en
Inventor
Andrei Yurievich EGOROV
Boris Ferko
Artem Alexandrovich KROKHIN
Yulia Romanovna ROMANOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nebolsin Vladimir Evgenievich Mr
Original Assignee
Nebolsin Vladimir Evgenievich Mr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2016111907A external-priority patent/RU2660562C2/ru
Application filed by Nebolsin Vladimir Evgenievich Mr filed Critical Nebolsin Vladimir Evgenievich Mr
Publication of AU2016350939A1 publication Critical patent/AU2016350939A1/en
Publication of AU2016350939A2 publication Critical patent/AU2016350939A2/en
Publication of AU2016350939B2 publication Critical patent/AU2016350939B2/en
Application granted granted Critical
Publication of AU2016350939B9 publication Critical patent/AU2016350939B9/en
Assigned to NEBOLSIN, VLADIMIR reassignment NEBOLSIN, VLADIMIR Request for Assignment Assignors: (<<Pharmenterprises Biotech>> Limited Liability Company)
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016350939A 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases Active AU2016350939B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2015147703 2015-11-06
RU2016111907 2016-03-30
RU2016111907A RU2660562C2 (ru) 2016-03-30 2016-03-30 Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
PCT/RU2016/050066 WO2017078577A2 (ru) 2015-11-06 2016-11-03 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Publications (4)

Publication Number Publication Date
AU2016350939A1 AU2016350939A1 (en) 2017-11-23
AU2016350939A2 AU2016350939A2 (en) 2018-02-08
AU2016350939B2 AU2016350939B2 (en) 2021-07-08
AU2016350939B9 true AU2016350939B9 (en) 2021-07-22

Family

ID=58662984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016350939A Active AU2016350939B9 (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases

Country Status (15)

Country Link
US (1) US10392604B2 (enExample)
EP (1) EP3382010A4 (enExample)
JP (1) JP6692835B2 (enExample)
KR (1) KR102604877B1 (enExample)
CN (1) CN108026515B (enExample)
AU (1) AU2016350939B9 (enExample)
CA (1) CA2991023C (enExample)
CU (1) CU24580B1 (enExample)
IL (1) IL255259B (enExample)
MA (1) MA43314A (enExample)
MX (1) MX380393B (enExample)
RU (1) RU2628690C2 (enExample)
SG (1) SG11201709122VA (enExample)
UA (1) UA125333C2 (enExample)
WO (1) WO2017078577A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217139A1 (ru) * 2017-05-26 2018-11-29 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
AU2018392799A1 (en) 2017-12-22 2020-05-28 Codagenix, Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе
AU2021342299A1 (en) * 2020-09-11 2023-04-13 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods of use thereof for prevention and treatment of influenza infections
AU2021378792A1 (en) * 2020-11-11 2023-05-04 California Institute Of Technology Multivalent carriers and related vaccine compositions
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2025041889A1 (ko) * 2023-08-24 2025-02-27 성신여자대학교 연구산학협력단 외래 항원을 발현하는 재조합 인플루엔자 바이러스 벡터 및 이를 포함하는 백신 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014504A1 (en) * 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US20120244183A1 (en) * 2009-07-30 2012-09-27 Adolfo Garcia-Sastre Influenza viruses and uses thereof
WO2014041082A1 (en) * 2012-09-12 2014-03-20 Medizinische Universität Wien Influenza virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1085904E (pt) * 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
US6468544B1 (en) * 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US7709190B2 (en) * 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
CN103282375B (zh) * 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014504A1 (en) * 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US20120244183A1 (en) * 2009-07-30 2012-09-27 Adolfo Garcia-Sastre Influenza viruses and uses thereof
WO2014041082A1 (en) * 2012-09-12 2014-03-20 Medizinische Universität Wien Influenza virus

Also Published As

Publication number Publication date
AU2016350939B2 (en) 2021-07-08
WO2017078577A3 (ru) 2017-06-29
BR112017025435A8 (pt) 2019-08-20
MX380393B (es) 2025-03-12
MA43314A (fr) 2018-10-03
IL255259A (en) 2018-04-30
JP6692835B2 (ja) 2020-05-13
SG11201709122VA (en) 2017-12-28
AU2016350939A1 (en) 2017-11-23
BR112017025435A2 (pt) 2018-09-11
AU2016350939A2 (en) 2018-02-08
CA2991023A1 (en) 2017-05-11
US20180245052A1 (en) 2018-08-30
EP3382010A2 (en) 2018-10-03
US10392604B2 (en) 2019-08-27
WO2017078577A2 (ru) 2017-05-11
UA125333C2 (uk) 2022-02-23
RU2628690C2 (ru) 2017-08-21
CN108026515A (zh) 2018-05-11
JP2018531578A (ja) 2018-11-01
HK1251616A1 (zh) 2019-02-01
CN108026515B (zh) 2022-03-11
MX2017015462A (es) 2018-03-07
KR20180067464A (ko) 2018-06-20
CU24580B1 (es) 2022-02-04
EP3382010A4 (en) 2019-03-27
CU20180035A7 (es) 2018-07-05
IL255259B (en) 2020-03-31
CA2991023C (en) 2025-05-13
RU2015147703A (ru) 2017-05-16
KR102604877B1 (ko) 2023-11-23

Similar Documents

Publication Publication Date Title
AU2016350939B9 (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
JP6870017B2 (ja) インフルエンザウイルス変異体およびその使用
ES2813347T3 (es) Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
JP3545418B2 (ja) インフルエンザの新規組換え温度感受性変異体
JP7691461B2 (ja) インフルエンザに対する免疫原性組成物
JP2019520338A (ja) ウマインフルエンザウイルス弱毒生ワクチン
RU2660562C2 (ru) Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
EA037571B1 (ru) Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
HK1251616B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
BR112017025435B1 (pt) Vírus influenza a atenuado, vetores do vírus influenza e seus usos, composições imunogênicas e farmacêuticas, e vacinas contra influenza
US12447204B2 (en) Prime-boost influenza vaccine
HK40005504B (en) Influenza virus mutants and uses therefor
Lee et al. Current status for influenza control

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 JAN 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 2015147703 06 NOV 2015 RU AND 2016111907 30 MAR 2016 RU

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEBOLSIN, VLADIMIR

Free format text: FORMER OWNER(S): (PHARMENTERPRISES BIOTECH LIMITED LIABILITY COMPANY)